Zai Lab Limited announced the dosing of the first participant in a global Phase 2 trial of its anti-IL-17 treatment, ZL-1102, for chronic plaque psoriasis.

To facilitate systematic and intuitive searching and research of ASCO conference clinical results, the synapse database has launched a new dedicated section for the 2024 ASCO conference clinical results.

Dyne Therapeutics Reveals Latest Clinical Results from ACHIEVE Study of DYNE-101 in DM1 and DELIVER Study of DYNE-251 in DMD Highlighting Significant Effects on Key Disease Indicators and Improvements in Several Functional Outcomes.

May 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

AT278 Ultra-Concentrated Rapid-Acting Insulin Shows Superiority in Phase I Trial for Overweight and Obese Type 2 Diabetics.

GigaGen Initiates Phase 1 Trial, Administers Initial Dose of GIGA-564 Anti-CTLA-4 Drug Candidate to Advanced Solid Tumor Patient.

GRI Bio Shows Promising Preclinical Results: Lead Candidate GRI-0621 Reduces Key Inflammatory and Fibrotic Factors in Idiopathic Pulmonary Fibrosis (IPF).

Rila Therapeutics Begins Dosing First Group in Phase 1 Trial of RLA-23174, an Innovative HIPK2 Allosteric Inhibitor, to Treat Chronic Kidney Disease and Fibrosis.

Innovent announces that the NMPA of China has accepted the NDA for IBI311, an IGF-1R antibody, for the treatment of Thyroid Eye Disease.

Replicate Bioscience has reported promising initial clinical outcomes for its self-replicating RNA (srRNA) vaccine, RBI-4000, which is designed to combat rabies.

The trial, which is evaluating a continuous subcutaneous delivery of low-dose lenalidomide combined with dexamethasone and bortezomib, is progressing faster than expected.

Biotechnology firm ProJenX has obtained approval from the European Union to conduct a Phase 1 clinical trial, known as PRO-101, for prosetin, a groundbreaking MAP4K inhibitor.